A small non-randomized retrospective study of a drug called pazopanib has shown that it increases children’s survival without ...

Kids with a rare bone cancer called Ewing sarcoma might live longer if prescribed pazopanib, a drug that blocks blood supply ...

Survival rates from small trial suggest that adding pazopanib to standard treatment for Ewing sarcoma in children may extend lives without adding severe toxicity.

A groundbreaking study led by researchers at Children’s Hospital Los Angeles offers critical insights into Ewing Sarcoma, a ...

Campo Verde will be without head coach Ryan Freeman for the third straight week as he takes time to be with his daughter, who ...

A research team at the Seville Biomedical Institute (IBis) has identified a new molecular mechanism that explains the high ...

Michael Perez has been running with a football for as long as he can remember. However, he received a medical diagnosis that ...

Ozekibart meets its primary endpoint in chondrosarcoma, demonstrating a statistically significant and clinically meaningful improvement in median progression-free ...

THURSDAY, Oct. 23, 2025 (HealthDay News) — Kids with a rare bone cancer might live longer if prescribed a drug that blocks ...

Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapeutics for oncology and rare diseases, today announced ...

Ewing sarcoma is a rare and serious diagnosis, largely impacting children. The disease only accounts for about 1% of all pediatric cancers in the U.S., with about 250 children diagnosed every year, ...